Ellume, Qiagen win clearance for TB test

By LabPulse.com staff writers

January 11, 2022 -- The QIAreach QuantiFeron-TB (QFT) tuberculosis (TB) test from Ellume and Qiagen has received approval from the Global Fund's Expert Review Panel for Diagnostics, clearing the way for its use in low-resource countries with a high TB burden.

With the approval, QIAreach QFT will now be available to public health programs and institutions in more than 100 countries that qualify for Global Fund and/or UNITAID resources. It will also be available through the Stop TB Partnership's Global Drug Facility, Ellume said.

Ellume and Qiagen partnered to develop QIAreach QFT, which was launched in October and has also received the CE Mark.

Ellume issues recall of test for SARS-CoV-2 infection
Ellume is recalling its COVID-19 Home Test for detecting SARS-CoV-2 infection due to its potential to produce false-positive results, according to the...
FDA issues alert on Ellume at-home COVID-19 tests
Some home tests for COVID-19 manufactured by Ellume may deliver false-positive results due to a manufacturing issue, according to a safety communication...
FDA issues EUA for Ellume's at-home COVID-19 test
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for an over-the-counter at-home diagnostic test for COVID-19...
Qiagen releases portable SARS-CoV-2 antigen test
Qiagen has launched a portable, digital SARS-CoV-2 antigen test that can analyze more than 30 swab samples per hour. The company developed the QIAreach...

Copyright © 2022 LabPulse.com

Last Updated ls 1/11/2022 3:42:36 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current